BB Biotech AG publishes its interim report
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report Media Release, April 23, 2021 BB Biotech AG publishes its interim report Based on the consolidated accounts of BB Biotech AG, net profit for the period ended March 31, 2021 amounted to CHF 221 mn (loss of CHF 758 mn in the same period 2020). For an investment company, the results reflect the share price development of the companies held in the portfolio. The interim report as at March 31, 2021 is available under report.bbbiotech.ch/Q121 or www.bbbiotech.com.
Company profile
23-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | BB BIOTECH AG |
Schwertstrasse 6 | |
8200 Schaffhausen | |
Switzerland | |
Phone: | +41 52 624 08 45 |
E-mail: | info@bbbiotech.com |
Internet: | www.bbbiotech.ch |
ISIN: | CH0038389992 |
WKN: | A0NFN3 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Mailand, SIX |
EQS News ID: | 1187763 |
End of Announcement | DGAP News Service |
|
1187763 23-Apr-2021 CET/CEST